Literature DB >> 7596170

Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias.

H D Menssen1, H J Renkl, U Rodeck, J Maurer, M Notter, S Schwartz, R Reinhardt, E Thiel.   

Abstract

The wt1 gene is located on chromosome 11p13 and encodes a zinc finger motif-containing transcription factor involved in regulation of growth and differentiation. Its expression was shown during embryonic development in various tissues as well as in a few human malignancies including acute leukemias. Using RT-PCR, we found wt1 gene expression in blast cells of the majority of 150 acute leukemia patients. Particularly, the wt1 transcript was detected in 12 of 14 (86%) pre-pre-B-ALL patients, in 33 of 41 (80%) cALL patients, in 23 of 31 (74%) T-ALL patients, and in 53 of 57 (93%) AML patients. Additionally, mononuclear cells from CML patients expressed the wt1 gene only when diagnosed with blast crisis. In contrast to acute human leukemias, mononuclear cells from reactive bone marrow (n = 4), and peripheral blood of healthy volunteers (n = 20), as well as normal peripheral CD34+ hematopoietic progenitors (n = 6) did not express the wt1 gene at detectable levels. Using the anti-WT1 MoAb 6F-H2 in an immunofluorescence assay on single cell level, we found the translated WT1 protein only in nuclei of leukemia blast cells but not in nuclei of normal CD34+ hematopoietic progenitor cells. Blast cells of 12 of 20 leukemia patients (60%) all tested positive for the wt1 gene expression by RT-PCR displayed a strong nuclear immunofluorescence. Its expression in the majority of human acute leukemias but not in normal mononuclear blood cells and normal CD34+ hematopoietic progenitors qualifies the wt1 gene transcript as a 'pan-acute leukemic' marker probably useful in monitoring minimal residual disease after chemotherapy and in detecting leukemic blast cells in purged or unpurged hematopoietic stem cell preparations intended to be used for autologous bone marrow transplantation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7596170

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  59 in total

Review 1.  Wilms' tumor gene WT1: its oncogenic function and clinical application.

Authors:  H Sugiyama
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

Review 2.  Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.

Authors:  Ann Van Driessche; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-01-30

3.  Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia.

Authors:  Sandra Heesch; Nicola Goekbuget; Andrea Stroux; Jutta Ortiz Tanchez; Cornelia Schlee; Thomas Burmeister; Stefan Schwartz; Olga Blau; Ulrich Keilholz; Antonia Busse; Dieter Hoelzer; Eckhard Thiel; Wolf-Karsten Hofmann; Claudia D Baldus
Journal:  Haematologica       Date:  2010-04-30       Impact factor: 9.941

Review 4.  Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances.

Authors:  Lauren McLaughlin; C Russell Cruz; Catherine M Bollard
Journal:  Ther Adv Hematol       Date:  2015-12

5.  Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation.

Authors:  Colin de Haar; Maud Plantinga; Nina Jg Blokland; Niek P van Til; Thijs Wh Flinsenberg; Viggo F Van Tendeloo; Evelien L Smits; Louis Boon; Lotte Spel; Marianne Boes; Jaap Jan Boelens; Stefan Nierkens
Journal:  Oncoimmunology       Date:  2015-05-27       Impact factor: 8.110

6.  Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.

Authors:  Nirali N Shah; David M Loeb; Hahn Khuu; David Stroncek; Tolu Ariyo; Mark Raffeld; Cindy Delbrook; Crystal L Mackall; Alan S Wayne; Terry J Fry
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-12       Impact factor: 5.742

Review 7.  Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?

Authors:  Celalettin Ustun; Jeffrey S Miller; David H Munn; Daniel J Weisdorf; Bruce R Blazar
Journal:  Blood       Date:  2011-08-31       Impact factor: 22.113

8.  Mechanisms of leukemia resistance to antibody dependent cellular cytotoxicity.

Authors:  Leonid Dubrovsky; Elliott Joseph Brea; Dmitry Pankov; Emily Casey; Tao Dao; Cheng Liu; David A Scheinberg
Journal:  Oncoimmunology       Date:  2016-08-03       Impact factor: 8.110

9.  Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.

Authors:  Katayoun Rezvani; Agnes S M Yong; Stephan Mielke; Bipin N Savani; Laura Musse; Jeanine Superata; Behnam Jafarpour; Carol Boss; A John Barrett
Journal:  Blood       Date:  2007-09-17       Impact factor: 22.113

10.  The lck promoter-driven expression of the Wilms tumor gene WT1 blocks intrathymic differentiation of T-lineage cells.

Authors:  Hanfen Li; Yoshihiro Oka; Akihiro Tsuboi; Tamotsu Yamagami; Toru Miyazaki; Sei-ichi Yusa; Kotomi Kawasaki; Yukiko Kishimoto; Momotaro Asada; Hiroko Nakajima; Keisuke Kanato; Sumiyuki Nishida; Tomoki Masuda; Masaki Murakami; Naoki Hosen; Manabu Kawakami; Hiroyasu Ogawa; Fritz Melchers; Ichiro Kawase; Yusuke Oji; Haruo Sugiyama
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.